ISR Holding: Signs an agreement with Catalent Inhalation - Redeye
Redeye is encouraged to learn that ISR has signed an agreement with Catalent Inhalation to scale-up its spray-dried nasal vaccine, powder formulation for its clinical phase III study.
ANNONS
Redeye is encouraged to learn that ISR has signed an agreement with Catalent Inhalation to scale-up its spray-dried nasal vaccine, powder formulation for its clinical phase III study.